Cell Therapy ApplicationsMetagenomi's cytosine base editors (CBEs) have shown high multiplexed protein knockout in T cells, showcasing the potential for cell therapy applications.
Financial PerformanceThe company remains well-capitalized with an operational runway extending into 2027, backed by ~$327M in cash and cash equivalents.
Gene Editing TechnologyMetagenomi's CAST system is capable of large scale DNA-templated integrations (>10,000 base pairs), rivaling others in the long sequence gene editing space.